Halozyme Announces Approval of Roche’s Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Halozyme Therapeutics, Inc. announced the approval of Roche’s Tecentriq® SC, using Halozyme’s ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency in Great Britain.